Pharmafile Logo
Pharmafocus logo
Advanced Search

cv

Showing 15 posts of 17 posts found.

Januvia image

Merck diabetes drug gets CV trial boost

June 9, 2015
Research and Development, Sales and Marketing Januvia, Merck, cv, diabetes, sitagliptin

Merck’s diabetes drug Januvia has been given a boost following worries over side effects for patients after a trial revealed …

News

Kowa launches new statin in the UK

August 20, 2010
Sales and Marketing Kowa, Recordati, cv, statin

A new statin has been launched in the UK by Japanese pharma company Kowa.Livazo (pitavastatin) has been approved by the …

News

European approval for 3-in-1 version of Exforge

October 23, 2009
Sales and Marketing Diovan, Exforge, Novartis, cv, hypertension

European regulators have approved an expanded version of Novartis’ high blood pressure treatment Exforge.Exforge was first approved in Europe in …

News

New 2-in-1 Valturna outperforms Diovan

October 1, 2009
Sales and Marketing Diovan, Novartis, Tekturna, cv, hyp, hypertension

Novartis has gained US approval for a combination of its blockbuster blood pressure drug Diovan and its follow-up product Tekturna/Rasilez.Valturna …

News

Effient ‘unlikely’ to takeover from Plavix

July 23, 2009
Research and Development, Sales and Marketing Effient, cv

News

Merck signs anticoagulant collaboration

July 17, 2009
Research and Development, Sales and Marketing Merck, cv

Merck has continued the trend of big pharma companies signing on the dotted line with small biotech outfits in a …

News

Merck acquires rights to atrial fibrillation candidate

April 16, 2009
Research and Development, Sales and Marketing Merck, cv

Merck has signed an agreement with Vancouver-based Cardiome Pharma to develop its new treatment for atrial fibrillation vernakalant.Merck will pay …

News

Bayer’s cardiovascular drug enters phase III

February 13, 2009
Research and Development, Sales and Marketing Bayer, cv

Bayer Schering Pharma has begun phase III trials of riociguat for treatment of two life-threatening conditions. Two trials will investigate …

News

Crestor study has ‘profound implications’ for NICE guidance

November 14, 2008
Sales and Marketing Crestor, cv, lipid

AstraZeneca's statin Crestor made national headlines this week when it was shown to dramatically reduce major cardiovascular events. New data …

News

Pradaxa approved by NICE

September 26, 2008
Sales and Marketing NICE, Pradaxa, clot, cv

NICE has recommended Boehringer Ingelheim's novel anti-clotting pill Pradaxa, giving it a marketing edge over Bayer's rival treatment Xarelto. Pradaxa …

News

Setback for Pfizer and BMS clotting drug

September 5, 2008
Sales and Marketing BMS, Pfizer, clot, cv

News

Experts play down Inergy cancer risk

September 5, 2008
Sales and Marketing Merck, cv

Heart specialists have told patients to continue taking Schering-Plough and Merck's cholesterol-lowering drug Inergy, despite a study indicating that it …

News

Study confers protective benefits on Micardis

April 4, 2008
Sales and Marketing cv

Boehringer Ingelheim's hypertension treatment Micardis has come out on top of Aventis's gold standard ACE inhibitor Tritace in a new …

News

Trial fails to enhance Inegy’s prospects

April 4, 2008
Sales and Marketing cv

Schering-Plough and Merck's much-touted anti-cholesterol combination Inegy has suffered a setback following a poor showing in the ENHANCE trial. Inegy …

News

Major leap in statin prescribing predicted

April 4, 2008
Sales and Marketing cv

News

Latest content

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024